• Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
中文

化合物分析和筛选服务

在人类组织模型中获得可靠的化合物数据。

采用出色、可高通量且经过验证的分析方法加速您的研发进程。
利用MIMETAS成功组织模型及专业经验来获得稳定的化合物响应数据。我们把经过验证的表型分析方法成功搭建到标准化的筛选工作流程中，通过这种创新的结合为前临床提供化合物筛选及鉴定服务。

安全性评价和化合物筛选
结合我们健康组织模型和评测数据中已探明的化合物副作用等丰富的经验及专业知识，减低早期研发项目中的风险。

药物释放和转运评估
评测障组织模型中药物转运情况，协助药物筛选和优化给药条。

如需了解更多关于化合物分析和筛选服务的信息，请查看我们的联系方式并致电我们。

获取更多信息/联系方式

人类组织和疾病模型专家

Other services

化合物分析和筛选
在人类组织模型中获得可靠的化合物数据。OrganoPlate® 平台提供经过验证的表型分析方法，满足您的药物发现和开发需求。

药物开发合作伙伴
我们的科学团队将与您并肩合作，让您在药物发现研究中如虎添翼。利用 OrganoPlate® 平台获得您专属的人类疾病生物学信息，让我们一起开创造福未来的疗法。

服务概述

知识中心

3D 细胞培养技术快速入门，了解 OrganoPlate® 如何满足您的研究需求。





知识中心

持续创新

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform
The 'I' in MIMETAS
'
Tackling challenges together.
What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "
What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.
The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data
The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!
The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.
The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable
The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Linda Gijzen
Scientific Project Lead
'
Tackling challenges together.
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models
Scientist
From a top pharma
New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context

 

 



By MIMETAS and Molecular Devices
Register here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology
Scientist
From a top pharma
News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

 

 



By MIMETAS and Molecular Devices
Register here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all